Latest fiscal year 2023 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2023, Panacea Life Sciences Holdings, Inc. reported revenue of $2M, up 46.6% year over year. Operating margin was -232.5% and net margin -336.1%, on a free-cash-flow margin of -66.7% with capital expenditure at 2.7% of revenue. Every figure is computed directly from PLSH's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2023 | $2M | -232.5% | -336.1% |
| FY2022 | $2M | -347.4% | -561.9% |
| FY2021 | $2M | -288.3% | -232.2% |
| FY2020 | $9M | -58.3% | -58.0% |
| FY2019 | $0M | -3087.5% | -2898.3% |
How does PLSH compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.